SYL1801 is an investigational siRNA therapy administered via eye drops, rather than intravitreal injection, to treat nAMD.

At ARVO 2025, in Salt Lake City, Utah, Ferhina Ali, MD, MPH, talked about her presentation on the early real-world use of aflibercept 8 mg in treatment-naive patients with neovascular age-related macu ...

Shifting from a regulatory role to driving innovation directly, Eydelman discusses how the Collaborative Community on ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

A machine learning model incorporating treated astigmatism and nuanced inputs is advancing the precision and personalization ...

Rishi Singh, MD, discusses faricimab's real-world effectiveness in treating diabetic macular edema, highlighting improved ...

The trial assessed the Valeda Light Delivery System in patients with dry (non-neovascular) age-related macular degeneration ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

At ARVO 2025, in Salt Lake City, Utah, Diana Do, MD, gave an update on the LIGHTSITE III study of photobiomodulation for dry age-related macular degeneration.

NCX 470, Nicox’s lead clinical product candidate, is a novel NO-donating bimatoprost eye drop with a dual mechanism of action ...

A recent analysis reveals that ellipsoidal zone-retinal pigment epithelial thickness predicts future visual loss in ...